Diabetic nephropathy and angiotensin converting enzyme inhibition; [Diabetik nefropati ve anjiotensin donusturucu enzim inhibisyonu]

Simple item page
dc.contributor.authorSaruc M.
dc.contributor.authorKursat S.
dc.contributor.authorKiliccioglu B.
dc.date.accessioned2024-07-22T08:25:53Z
dc.date.available2024-07-22T08:25:53Z
dc.date.issued1998
dc.description.abstractDiabetic nephropathy is the single most common cause of renal failure leading to end stage renal disease. The cost of providing dialysis for uremic diabetics is very expensive. Diabetic nephropathy is also associated with markedly increased morbidity and mortality for the patient with diabetes mellitus who develops this complication. Angiotensin converting enzyme inhibition has protective effects on renal functions and structure in diabetic nephropathy. This protection is probably independent of the systemic hypotensive effect of these agents. That is why effective antihypertensive treatment with angiotensin converting enzyme inhibitors in patients with diabetic nepropathy results in a large reduction in albuminuria and a low rate of decline in kidney function. As a conclusion, all patients with diabetes and documented diabetic glomerulopathy should be treated with an angiotensin converting enzyme inhibitor.
dc.identifier.issn10165134
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20654
dc.language.isoTurkish
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectantihypertensive therapy
dc.subjectdiabetic nephropathy
dc.subjectdialysis
dc.subjecthuman
dc.subjectkidney failure
dc.subjectproteinuria
dc.subjectshort survey
dc.subjecturemia
dc.titleDiabetic nephropathy and angiotensin converting enzyme inhibition; [Diabetik nefropati ve anjiotensin donusturucu enzim inhibisyonu]
dc.typeShort survey

Files

Collections

Scopus Koleksiyonu